MEDICLIN Reports Strong Nine-Month Performance with 42% Operating Profit Growth
TL;DR
MEDICLIN's 42% operating profit surge to EUR 48.9 million demonstrates strong financial performance and competitive positioning in the healthcare market.
MEDICLIN achieved 5.1% sales growth to EUR 586.9 million through segment optimization while maintaining stable 86.8% capacity utilization across operations.
MEDICLIN's improved financial results support continued healthcare delivery across 31 clinics and 6 care facilities, enhancing patient care for communities.
MEDICLIN transformed its acute segment from a EUR 3.8 million loss to EUR 0.7 million profit while growing post-acute sales by 9.3%.
Found this article helpful?
Share it with your network and spread the knowledge!
MEDICLIN Aktiengesellschaft reported consolidated group sales of €586.9 million in the first nine months of 2025, representing a 5.1% increase compared to the same period last year. The company's group operating result showed substantial improvement, reaching €48.9 million compared to €34.5 million in the first nine months of 2024, marking a 42% increase in profitability. Overall capacity utilization across the group remained stable at 86.8%, slightly above the previous year's level of 86.0%.
The post-acute segment emerged as the strongest performer, with sales increasing by 9.3% to €394.6 million and segment operating result rising by €9.6 million to €47.6 million. This segment's cost of materials ratio improved by 0.9 percentage points to 19.5%, while personnel expenses increased by 9.4% to €205.0 million, primarily due to salary increases and higher employee numbers. The personnel expense ratio in this segment remained unchanged at 51.9%.
In the acute segment, developments were significantly influenced by the sale of the former MEDICLIN Herzzentrum Coswig, resulting in a 3.2% decrease in segment sales. However, the segment showed remarkable operational improvement, with operating result turning positive at €0.7 million compared to a loss of €3.8 million in the same period last year, representing a 117.2% improvement. The cost of materials fell by 4.8% to €47.6 million, while personnel expenses decreased by 4.8% to €101.0 million.
The nursing care segment reported sales of €18.6 million but recorded an operating loss of €0.4 million, down €0.5 million from the previous year. Meanwhile, the service segment showed positive momentum with sales increasing to €74.8 million and operating result improving by €0.8 million to €1.0 million.
The Management Board confirmed its guidance for the 2025 financial year, expecting consolidated group sales growth between 2.0% and 5.0% and consolidated group EBIT between €53.0 million and €64.0 million. CFO Tino Fritz commented, "In view of the current conditions and typical seasonal effects in the fourth quarter, we continue to assess business development as solid. With the current quarterly results, we are demonstrating that we will achieve our original annual guidance and successfully conclude the current financial year."
The interim report as of September 30, 2025, is available in German and English at https://www.mediclin.de. The original release can be viewed on https://www.newmediawire.com.
Curated from NewMediaWire
